Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States.
The last earnings update was 82 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Krystal Biotech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Krystal Biotech's earnings available for a low price, and how does
this compare to other companies in the same industry?
Krystal Biotech's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Krystal Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Krystal Biotech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Krish S. Krishnan, M.S., M.B.A. has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. Krishnan is Co-Owner of Krishnan Family Trust. He served as the Chief Operating Officer of Intrexon Corporation from December 5, 2011 to March 21, 2016. Mr. Krishnan served as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He served as the Chief Operating Officer, Head of Corporate Development and Director of Business Development and Strategy of Third Security, LLC. and served as its Senior Managing Director from 2001 to 2008. He served as Managing Principal at Ariba Inc. before joining Third Security. Mr. Krishnan was actively involved with a start-up venture. He has many years of experience in the life sciences industry. He served as Chief Operating Officer, Chief Financial Officer of New River Pharmaceuticals Inc. from April 2004 to April 2007. He served as Secretary of New River Pharmaceuticals Inc. since April 2004 and also served as its Principal Accounting Officer. He served as President and Chief Executive Officer of Harvest Pharmaceuticals Inc. Mr. Krishnan served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy and started his career as an industrial engineer with E.I. Dupont de Nemours. He held position with KPMG Peat Marwick. He serves as a Director and Member of Advisory Board of Talkflow Systems, LLC. He serves as a Director of Pinnacle Pharmaceuticals, Inc. He has been Director of Thar Pharmaceuticals, Inc. since June 2016. He serves on the Boards of Directors of a number of Third Security's portfolio companies. He served as a Director of New River Pharmaceuticals Inc. from March 2003 to April 2007. He served as a Director of Biotie Therapies Corp. from 2008 to 2009. Mr. Krishnan received a B.S. in Mechanical Engineering from the Indian Institute of Technology (IIT), MS in Engineering from the University of Toledo and MBA in Finance from The Wharton School at the University of Pennsylvania.
Insufficient data for Krish to compare compensation growth.
Krish's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Krystal Biotech management team is less than 2 years, this suggests a new team.
Vice President of Product Development
Chief Financial Officer
Human Resources & Office Manager
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Krystal Biotech board of directors is less than 3 years, this suggests a new board.
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company’s lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.